Category

• Pipeline4

Organizations

• Bausch + Lomb64
• Eyes On Eyecare42
• Alcon, Inc.41
• American Optometric Association34
• Harrow26
• Glaukos25
• Regeneron21
• Aldeyra Therapeutics20
• Sight Sciences19
• American Academy Of Ophthalmology18

Tags

• Retinitis Pigmentosa3
• FDA2
• Clinical Trials2
• Retina2
• Geographic Atrophy1

• Organizations: Endogena Therapeutics✕

Clear all

Pipeline

FDA clears Endogena's IND for GA investigational compound

A first-in-human study for EA-2351 is set to kick off in 2024.

Pipeline

Endogena concludes enrollment ahead of schedule for RP trial

Phase 1/2a dose expansion trial is assessing the safety and tolerability of EA-2353.

Pipeline

Endogena Therapeutics concludes dose-escalation stage in RP trial

Company announces successful completion for intravitreal injections of EA-2353.

Pipeline

Endogena Therapeutics earns Fast Track designation for RP treatment

EA-2353 is a gene-independent, small-molecule approach with the potential to restore or preserve visual function.